Food supplement pharmaceutical company for sale in TOP5 EU market.
Products are promoted to doctors via the sales force.
No manufacturing is involved since products are manufactured by third parties.
Financials: 10M euros annual revenue, 1M euros EBITDA. No debts.
Shareholders are willing to sell 100% of the shares. We are looking for a buy-side mandate.
Well established, growing and profitable pharmaceutical company in the USA, which develops, promotes and distributes its products in all 50 states.
The product portfolio includes non-addictive pain relief products, such as ointments, gels, patches and surgery recovery formulations to help avoid infection and wound complications before and after surgery. Several products are in pipeline.
The company does not own any plants and manufacturers. Its products use FDA-approved CMOs located in the USA and China. No warning letters from the FDA during the last years.
6 experienced employees in Operations, Marketing, Sales, Finance, and Administration.
Financials: annual revenue 6M+ USD, Net Income 4M+ USD, no debts. Profit stable every year.
Profitable and fast-growing privately owned R&D and factory of food supplements. The company has 16 employees and owns an R&D lab (chemical and microbiological) as well as a factory that produces food supplements in different forms - tablets, capsules, and oral liquids.
The facilities might be upgraded to the EU GMP level where pharmaceuticals could be produced.
The company possesses its own brands and also provides contract manufacturing services. It has been recently approved by Amazon as a new selling channel.
Financials: 2020E annual revenue of 3.5M euros, EBITDA 1M euros. The selling process will be organized at the end 2022.
Well-established pharmaceutical service providing company, operating 17, is headquartered in Ireland and operates in about 40 countries. It provides quality services to the pharma industry and other regulated sectors.
The company has 26 associates offering core services in the areas of pharmaceutical regulatory support services, auditing, training, consulting, service of a qualified person, and responsible person support in the EU as well as offering importation capability for IMP and authorized medicines.
All associates have extensive industry experience of 20 years on average. Each associate has held a senior management role in GMP environments.
Auditing: IRCA certified auditors to audit against ICH Q7, USA FDA, EU GMP, WHO, Health Canada ISO13485 ISO9001 ISO17025 processes audited: drug substance (API), drug product (dosage form), medical devices laboratories, contract packaging, clinical trial materials (IMP).
Training: auditing (internal), auditing (pharmaceutical lead auditor), validation, GMP, GLP, good distribution practices/pharmaceutical, wholesaling quality systems, inspection preparation.
Excellent feedback consulting: factory start-up, managing deviations, auditing programs, line clearance, inspection preparation, operating procedure generation, obtaining authorizations from HPRA (MIA, WDA, etc).
EU QP Importation and QP Certification: EU IMP importation and QP certification, EU commercial batch QP certification, EU IMP and commercial batch testing EU product distribution.
Qualified persons: EU/EEA certificated qualified persons; qualified for all dosage forms (steriles, solids, IMPs, etc).
Short-term or long-term contracts; fast approval onto manufacturing authorization responsible persons: EU/EEA certificated responsible persons, qualified for wholesaling of all dosage forms (steriles, solids, IMPs, etc).
Short-term or long-term contracts, fast approval onto wholesaling dealers authorization proven track record - has supported over 110 clients and operates internationally in over 40 countries including the Americas, Europe, Australia, and Asia. Has assisted multiple companies in obtaining authorizations from the European competent authorities, encompassing wholesaler dealer’s authorizations, manufacturer’s authorizations, and IMP authorizations.
Apps for the iPhone and Android platforms that bring global GMP regulations direct to your mobile device. Apps will keep you up to date with the latest GMP regulations as well as key GxP legislation and related pharma industry guidance documents.
Financials: 1.41 euro million turnover, profit of 0.12 euros million. Adjusted EBITDA 0.57 million euros. The expected sale price is 5.4 million euros.
We do have more profitable and growing pharmaceutical companies and assets for sale in the USA and Europe, which are not published here.
We are regularly receiving new opportunities, so do not hesitate and send us an email to [email protected] in case you are looking for a specific acquisition indicating the target region or market.
Find out how you can acquire pharmaceutical business or how you can sell one.
"Pipelinepharma is continuously generating us leads of pharmaceutical companies for sale in different regions and markets. One of such leads in Europe has been successfully acquired by Aristo Pharma"
“We can warmly recommend Pipelinepharma and Mindaugas, whose pugnacious efforts brought us the right buyer, leading to a win-win situation for the parties involved and a good deal overall”